JP2005509663A - 癌治療のための方法 - Google Patents
癌治療のための方法 Download PDFInfo
- Publication number
- JP2005509663A JP2005509663A JP2003545313A JP2003545313A JP2005509663A JP 2005509663 A JP2005509663 A JP 2005509663A JP 2003545313 A JP2003545313 A JP 2003545313A JP 2003545313 A JP2003545313 A JP 2003545313A JP 2005509663 A JP2005509663 A JP 2005509663A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- day
- days
- compound
- gemcitabine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *[n]1c2ccccc2c(C(C(N2)=O)=C(c3c[n](*)c4cc([N+]([O-])=O)ccc34)C2=O)c1 Chemical compound *[n]1c2ccccc2c(C(C(N2)=O)=C(c3c[n](*)c4cc([N+]([O-])=O)ccc34)C2=O)c1 0.000 description 2
- HVBSAWHDFKYMGJ-UHFFFAOYSA-N CC(C1)C=Cc2c1[nH]cc2C(C(N1)=O)=C(C2=CN(C)C(C)(C3)C2(C)CC=C3[N+]([O-])=O)C1=O Chemical compound CC(C1)C=Cc2c1[nH]cc2C(C(N1)=O)=C(C2=CN(C)C(C)(C3)C2(C)CC=C3[N+]([O-])=O)C1=O HVBSAWHDFKYMGJ-UHFFFAOYSA-N 0.000 description 1
- JWZBMXHVWNWEOI-UHFFFAOYSA-N C[n]1c2cc([N+]([O-])=O)ccc2c(C(C(N2)=O)=C(C3=CC(CO)c4c3cccc4)C2=O)c1 Chemical compound C[n]1c2cc([N+]([O-])=O)ccc2c(C(C(N2)=O)=C(C3=CC(CO)c4c3cccc4)C2=O)c1 JWZBMXHVWNWEOI-UHFFFAOYSA-N 0.000 description 1
- WPOXORBYXYNRFB-UHFFFAOYSA-N C[n]1c2cc([N+]([O-])=O)ccc2c(C(C(N2)=O)=C(c3c[nH]c4ccccc34)C2=O)c1 Chemical compound C[n]1c2cc([N+]([O-])=O)ccc2c(C(C(N2)=O)=C(c3c[nH]c4ccccc34)C2=O)c1 WPOXORBYXYNRFB-UHFFFAOYSA-N 0.000 description 1
- HNHUTZDWNIUKMK-UHFFFAOYSA-N C[n]1c2cc([N+]([O-])=O)ccc2c(C(C(NC2=O)=O)=C2C2=CC(CO)Cc3c2cccc3)c1 Chemical compound C[n]1c2cc([N+]([O-])=O)ccc2c(C(C(NC2=O)=O)=C2C2=CC(CO)Cc3c2cccc3)c1 HNHUTZDWNIUKMK-UHFFFAOYSA-N 0.000 description 1
- OVSKGTONMLKNPZ-UHFFFAOYSA-N C[n]1c2ccccc2c(C(C(N2)=O)=C(c3c[n](C)c4cc([N+]([O-])=O)ccc34)C2=O)c1 Chemical compound C[n]1c2ccccc2c(C(C(N2)=O)=C(c3c[n](C)c4cc([N+]([O-])=O)ccc34)C2=O)c1 OVSKGTONMLKNPZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33397701P | 2001-11-20 | 2001-11-20 | |
| US60/333,977 | 2001-11-20 | ||
| PCT/EP2002/012572 WO2003043632A2 (en) | 2001-11-20 | 2002-11-11 | Use of bisindolmaleimide and gemcitabine for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005509663A true JP2005509663A (ja) | 2005-04-14 |
| JP2005509663A5 JP2005509663A5 (enExample) | 2005-12-22 |
Family
ID=23305029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003545313A Pending JP2005509663A (ja) | 2001-11-20 | 2002-11-11 | 癌治療のための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030139373A1 (enExample) |
| EP (1) | EP1448189A2 (enExample) |
| JP (1) | JP2005509663A (enExample) |
| CN (1) | CN1589143A (enExample) |
| AR (1) | AR037543A1 (enExample) |
| AU (1) | AU2002366195A1 (enExample) |
| CA (1) | CA2465807A1 (enExample) |
| WO (1) | WO2003043632A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102373A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Method for administration of cancer therapeutic |
| EP2711008A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer |
| EP2711007A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer |
| EP2711009A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | Compounds for use in treating or preventing primary and metastatic breast and prostate cancer |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| RU2762573C2 (ru) | 2016-11-15 | 2021-12-21 | Новартис Аг | Доза и режим введения для ингибиторов взаимодействия hdm2 с p53 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3587500T2 (de) * | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| SK75289A3 (en) * | 1988-02-10 | 1998-05-06 | Hoffmann La Roche | Substituted pyrroles, their use for producing a drug, and the drug on their base |
| PE91698A1 (es) * | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
| HRP20000585B1 (en) * | 1998-03-17 | 2009-02-28 | F. Hoffmann - La Roche Ag | Substituted bisindolymaleimides for the inhibition of cell proliferation |
| US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| US6281356B1 (en) * | 1999-12-22 | 2001-08-28 | Hoffmann-La Roche Inc. | Substituted pyrroles |
| AU2001271257A1 (en) * | 2000-06-29 | 2002-01-14 | Eli Lilly And Company | Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy |
| US6482847B2 (en) * | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
| US6548531B2 (en) * | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
-
2002
- 2002-11-08 US US10/290,652 patent/US20030139373A1/en not_active Abandoned
- 2002-11-11 EP EP02790352A patent/EP1448189A2/en not_active Withdrawn
- 2002-11-11 JP JP2003545313A patent/JP2005509663A/ja active Pending
- 2002-11-11 WO PCT/EP2002/012572 patent/WO2003043632A2/en not_active Ceased
- 2002-11-11 CA CA002465807A patent/CA2465807A1/en not_active Abandoned
- 2002-11-11 CN CNA028230426A patent/CN1589143A/zh active Pending
- 2002-11-11 AU AU2002366195A patent/AU2002366195A1/en not_active Abandoned
- 2002-11-18 AR ARP020104419A patent/AR037543A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1589143A (zh) | 2005-03-02 |
| EP1448189A2 (en) | 2004-08-25 |
| AU2002366195A8 (en) | 2003-06-10 |
| WO2003043632A3 (en) | 2003-12-11 |
| AR037543A1 (es) | 2004-11-17 |
| CA2465807A1 (en) | 2003-05-30 |
| WO2003043632A2 (en) | 2003-05-30 |
| AU2002366195A1 (en) | 2003-06-10 |
| US20030139373A1 (en) | 2003-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117919235A (zh) | 一种萘酰胺化合物治疗kras突变相关疾病的用途 | |
| CN105311029A (zh) | 抗肿瘤活性的喹啉衍生物 | |
| CN109675041A (zh) | 用于治疗癌症的系统、方法和制剂 | |
| WO2023092943A1 (zh) | 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用 | |
| CN103491952A (zh) | 用于治疗癌症的新颖联合疗法 | |
| JPH0296524A (ja) | 抗癌活性を有する治療薬組成物と癌の治療方法 | |
| CN109641009A (zh) | 抗肿瘤剂、抗肿瘤效果增强剂及抗肿瘤用试剂盒 | |
| US6548531B2 (en) | Method for cancer therapy | |
| AU2004220205B2 (en) | Antitumor effect potentiator and antitumor agent | |
| AU2002246080A1 (en) | Method for Cancer Therapy | |
| US20030139373A1 (en) | Method for cancer therapy | |
| JP2557303B2 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| CN118787649B (zh) | 一种治疗非小细胞肺癌kras g12c突变的药物组合物及其应用 | |
| WO2025087460A1 (zh) | 一种吡啶并吡唑衍生物药物组合物及其应用 | |
| CN118059249A (zh) | 喹唑啉类化合物与三代egfr抑制剂在治疗非小细胞肺癌的联合用药物中的用途 | |
| CN101181230A (zh) | 一种治疗实体肿瘤的雌二醇氮芥缓释植入剂 | |
| TWI904148B (zh) | 包含蛋白激酶抑制劑和化療藥物的藥物組合物及其用途 | |
| KR20130140052A (ko) | 증식성 질환의 치료를 위한 베바시주맙 및 2,2-다이메틸-N-((S)-6-옥소-6,7-다이하이드로-5H-다이벤조[b,d]아제핀-7-일)-N''-(2,2,3,3,3-펜타플루오로-프로필)-말론아미드의 조합 | |
| US11986507B1 (en) | Micronutrient composition to improve men's health | |
| CN110339195A (zh) | 用于治疗胆管癌的喹啉衍生物 | |
| CN117357528A (zh) | 一种激酶抑制剂的新用途 | |
| JPWO2005007155A1 (ja) | 医薬組成物 | |
| JPH10505323A (ja) | ２−ハロ−２’−デオキシアデノシンによる炎症性腸疾患の治療 | |
| TW202317135A (zh) | 選擇性雌激素受體共價拮抗劑與cdk4/6抑制劑聯合在製備治療乳腺癌藥物中的用途 | |
| EP1180027A1 (en) | Method for the prevention or reduction of cardiovascular events associated with coronary intervention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071127 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080422 |